EU-IN_VITRO_MEDICAL_DEVICES-ART_3_ANX_1
EU-IN_VITRO_MEDICAL_DEVICES-ART_3_ANX_1
In Vitro Diagnostic Medical Devices Directive - Hazardous Substances
EU. Hazardous Substances for Purposes of Article 3 & Annex I (Essential Requirements), Directive 98/79/EC on In Vitro Diagnostic Medical Devices, 7 December 1998
This list contains a non-exhaustive inventory of hazardous substances for purposes of essential requirements (Article 3 and Annex I) for general safety, design, manufacture and hazard communication of in vitro diagnostic medical devices. It is derived from: Table 3 of Annex VI to CLP, REACH Candidate List of SVHCs, and Directive 2000/54/EC's Annex III (Biological Agents list). Note that Regulation 2017/746/EU on in vitro diagnostic medical devices was published in the EU Official Journal on 5 May 2017. With few exceptions specified in Articles 112 and 113 of this Regulation, Directive 98/79/EC is repealed, and the rules pursuant to 2017/746/EU apply, from 26 May 2022.
Last updated 16 May 2024. Database contains 4821 unique substances/entries.
Filter the list
|
205-223-9
|
135-88-6
|
Carc. 2; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
|||
|
BTAD
|
416-470-9
|
170292-97-4
|
Eye Irrit. 2 |
||
|
DS 100
|
415-060-7
|
1379678-87-1
|
Eye Dam. 1; Skin Sens. 1 |
||
|
423-530-8
|
152828-23-4
|
STOT RE 1; Acute Tox. 4 |
|||
|
425-300-2
|
186450-73-7
|
Skin Sens. 1 |
|||
|
204-658-1
|
123-86-4
|
Flam. Liq. 3; STOT SE 3 |
|||
|
205-480-7
|
141-32-2
|
Flam. Liq. 3; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2; Skin Sens. 1 |
|||
|
EP 389
|
407-730-2
|
104958-67-0
|
Eye Irrit. 2; Skin Sens. 1 |
||
|
203-700-6
|
109-74-0
|
Flam. Liq. 2; Acute Tox. 3 |
|||
|
PREVENTOL VP OC 3061
|
423-990-1
|
149118-66-1
|
Acute Tox. 4; Eye Dam. 1 |
||
|
DIMETHYLPAPAMIDOLAURDIMONIUM TOSYLATE
|
421-130-8
|
156679-41-3
|
Eye Dam. 1; Skin Sens. 1 |
||
|
203-135-5
|
103-69-5
|
Acute Tox. 3; STOT RE 2 |
|||
|
203-777-6
|
110-54-3
|
Flam. Liq. 2; Repr. 2; Asp. Tox. 1; STOT RE 2; Skin Irrit. 2; STOT SE 3 |
|||
|
202-969-7
|
101-72-4
|
Acute Tox. 4; Skin Sens. 1 |
|||
|
817-852-1
|
1228284-64-7
|
Carc. 2; Repr. 2 |
|||
|
429-340-1
|
186295-11-4
|
Acute Tox. 4; Eye Dam. 1 |
|||
|
202-870-9
|
100-61-8
|
Acute Tox. 3; STOT RE 2 |
|||
|
204-624-6
|
123-39-7
|
Repr. 1B; Acute Tox. 4 |
|||
|
431-060-1
|
153719-38-1
|
Acute Tox. 4; Skin Sens. 1 |
|||
|
426-150-0
|
121246-28-4
|
Skin Sens. 1 |
|||
|
205-547-0
|
142-59-6
|
Acute Tox. 4; STOT SE 3; Skin Sens. 1 |
|||
|
A complex combination of hydrocarbons obtained from a distillation process of crude petroleum. It consists predominantly of hydrocarbons having carbon numbers in the range of C8 through C12 and boiling in the range of approximately 130°C to 210°C (266°F to 410°F).
|
309-945-6
|
101631-20-3
|
Carc. 1B; Muta. 1B; Asp. Tox. 1 |
||
|
A complex combination of hydrocarbons obtained by fractionation from hydrodesulphurised coker distillate. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 to C11 and boiling in the range of approximately 23°C to 196°C (73°F to 385°F).
|
309-879-8
|
101316-76-1
|
Carc. 1B; Muta. 1B; Asp. Tox. 1 |
||
|
A complex combination of hydrocarbons obtained by subjecting a petroleum naphtha to a sweetening process to convert mercaptans or to remove acidic impurities. It consists predominantly of hydrocarbons having carbon numbers predominantly in the range of C5 through C8 and boiling in the range of approximately 20°C to 130°C (68°F to 266°F).
|
309-976-5
|
101795-01-1
|
Carc. 1B; Muta. 1B; Asp. Tox. 1 |
||
|
215-657-0
|
1338-02-9
|
Flam. Liq. 3; Acute Tox. 4 |
|||
|
205-073-4
|
132-67-2
|
Acute Tox. 4 |
|||
|
240-841-2
|
16812-54-7
|
Carc. 1A; Muta. 2; STOT RE 1; Skin Sens. 1 |
|||
|
239-086-1
|
14998-37-9
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Acute Tox. 4; Resp. Sens. 1; Skin Sens. 1 |
|||
|
242-522-3
|
18718-11-1
|
Carc. 1A; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
238-511-8
|
14507-36-9
|
Carc. 1A; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
237-396-1
|
13770-89-3
|
Carc. 1A; Muta. 2; Repr. 1B; Acute Tox. 4; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
238-753-4
|
14708-14-6
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
235-723-2
|
12619-90-8
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
|||
|
234-493-0
|
12007-00-0
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
|||
|
238-766-5
|
14721-18-7
|
Carc. 1A; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
235-103-1
|
12068-61-0
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
|||
|
238-596-1
|
14550-87-9
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
236-665-0
|
13462-88-9
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
239-646-5
|
15586-38-6
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
233-071-3
|
10028-18-9
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
235-008-5
|
12054-48-7
|
Carc. 1A; Repr. 1B; Muta. 2; STOT RE 1; Acute Tox. 4; Skin Irrit. 2; Resp. Sens. 1; Skin Sens. 1 |
|||
|
236-666-6
|
13462-90-3
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
-
|
16039-61-5
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
236-068-5
|
13138-45-9
|
Ox. Sol. 2; Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Acute Tox. 4; Skin Irrit. 2; Eye Dam. 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
234-823-3
|
12035-36-8
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
|||
|
237-124-1
|
13637-71-3
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Skin Corr. 1B; Resp. Sens. 1; Skin Sens. 1 |
|||
|
237-563-9
|
13842-46-1
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Acute Tox. 4; Resp. Sens. 1; Skin Sens. 1 |
|||
|
235-379-3
|
12201-89-7
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
|||
|
237-205-1
|
13689-92-4
|
Carc. 1A; Muta. 2; Repr. 1B; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||
|
238-278-2
|
14332-34-4
|
Carc. 1A; STOT RE 1; Resp. Sens. 1; Skin Sens. 1 |
|||